Innoviva

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alkermes

Atara Biotherapeutics

Autolus Therapeutics

Retrophin

Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.

5 Beaten-Down Biotech Stocks Set to Rebound in 2020

AbbVie

Celestica

Sony

Vodafone Group

These undervalued stocks have been hit hard lately, but they still have what it takes to make a comeback, making them solid stocks to buy.
The post 5 Undervalued Stocks to Buy appeared first on InvestorPlace.

5 Undervalued Stocks to Buy

Innoviva Inc. Is A Buy

Biogen

Mylan

Novartis

Regeneron Pharmaceuticals

Theravance Biopharma

With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.

7 Biotech Stocks to Buy With Plenty of Power in the Pipeline        

Altra Industrial Motion

Benchmark Electronics

Brooks Automation

Pitney Bowes

PetMed Express

Qudian

SYNNEX

Voya Financial

WESCO

Petmed, Innoviva and Pitney Bowes are among some of the best small-cap stocks to buy now, after a recent drubbing.

10 Small-Cap Stocks That Look Like Bargains

Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

News for Innoviva Stock (INVA)